Francesca Romana Mauro | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	AMERICAN JOURNAL OF HEMATOLOGY	2021
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib	CANCERS	2021
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study	BLOOD	2021
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases	EUROPEAN JOURNAL OF HAEMATOLOGY	2021
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group	AMERICAN JOURNAL OF HEMATOLOGY	2020
Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study	HAEMATOLOGICA	2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study	LEUKEMIA	2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia	BLOOD	2020
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations	BRITISH JOURNAL OF HAEMATOLOGY	2020
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)	HAEMATOLOGICA	2020
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia	HAEMATOLOGICA	2020
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	HAEMATOLOGICA	2020
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	CANCERS	2020
Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	2020
Front-line therapy for elderly chronic lymphocytic leukemia patients: bendamustine plus rituximab or chlorambucil plus rituximab? Real-life retrospective multicenter study in the Lazio region	FRONTIERS IN ONCOLOGY	2020
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114).	HemaSphere 2020; 4 (S1) p 290	2020
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114)	Haematologica, 2020; 105(s2):s28	2020
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab	LEUKEMIA	2019
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia	HAEMATOLOGICA	2019
Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment	LEUKEMIA RESEARCH	2019

Progetti di Ricerca

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) OR OTHER ANTICOAGULANT/ANTIAGGREGANT TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB: A MULTICENTER, REAL WORLD, OBSERVATIONAL STUDY.
CLINICAL AND SEROLOGICAL RESPONSE TO THE PNEUMOCOCCAL VACCINATION AFTER CHEMOIMMUNOTHERAPY OR ON KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Severe infections and pneumonia in relapsed/ refractory (R/R) patients with chronic lymphocytic leukemia (CLL) treated in the real world with bendamustine and rituximab (BR) chemoimmunotherapy or the kinase inhibitors (KIs) ibrutinib or idelalisib.
BCR PATHWAY AND BCL-2 INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED IN THE CLINICAL PRACTICE: OUTCOMES AND REASONS FOR TREATMENT DISCONTINUATION. A REAL WORLD OBSERVATIONAL STUDY